Arovella Therapeutics Ltd has released a press release.
CLDN18.2 CAR iNKT Cell Preclinical Data Update
Earlier from Arovella Therapeutics
- Half Year Report and Appendix 4D
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Quarterly Activities/Appendix 4C Cash Flow Report
- Arovella Therapeutics: appoints former CSL CSO Dr Andrew Nash as Non-executive Director